1 / 31

Chemical Biology 1 – Pharmacology

Chemical Biology 1 – Pharmacology. 10-17-14. Methods for studying protein function – Loss of Function. 1. Gene knockouts 2. Conditional knockouts 3. RNAi 4. Pharmacology (use of small molecules to turn off protein function). pre-translational. Pharmacology. Advantages

Télécharger la présentation

Chemical Biology 1 – Pharmacology

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Chemical Biology 1 –Pharmacology 10-17-14

  2. Methods for studying protein function – Loss of Function • 1. Gene knockouts • 2. Conditional knockouts • 3. RNAi • 4. Pharmacology (use of small molecules to turn off protein function) pre-translational

  3. Pharmacology • Advantages • 1. Fast time scale • 2. Only perturbs targeted sub-domains • 3. graded dose response - tunability • 4. Most drugs are small molecules • Disadvantage • Unlike genetic methods it is difficult to identify ligands that are highly selective for a target. Weiss WA, Taylor SS, Shokat KM. “Recognizing and exploiting differences between RNAi and small-molecule inhibitors.” Nat Chem Biol. 2007 Dec;3(12):739-44.

  4. Time Scale and Specificity

  5. Small molecules are subdomain specific Example: PAK1 Kinase Small molecules affect only one domain, while pre-translational methods remove the entire protein from the cell.

  6. Tunability Allows the amount of inhibition/activity that is necessary

  7. Reverse Chemical Genetics (Pharmacology) 1. Identify a protein target of interest • Develop an activity assay (enzymes) or a binding assay (protein-ligand interactions) to screen compounds 2. Test biased or unbiased panels of compounds against protein target of interest 3. Optimize your initial lead compound by making analogs (SAR) and by using any additional biochemical/structural information. In parallel, screen optimized analogs against other targets (selectivity)

  8. Major challenges • Druggability • Many proteins do not appear to make favorable interactions with drug-like small molecules Molecular Weight <900 Da Kd < 1 mM (∆G < -8.4 kcal/mol) No more than one or two fixed charges • Estimated that only ~10% of all proteins are druggable Hopkins and Groom, Nat Reviews Drug Disc, 2002

  9. Major challenges • Selectivity • Finding selective agonists and antagonists is very challenging • Knowing which other proteins to counterscreen is difficult (easier for mechanism-based or enzyme family-directed ligands) In some cases, chemistry and genetics can be used to circumvent these problems. Knight ZA, Shokat KM. “Chemical genetics: where genetics and pharmacology meet. Cell. 2007 Feb 9;128(3):425-30.” Koh JT. “Engineering selectivity and discrimination into ligand-receptor interfaces.” Chem Biol. 2002 Jan;9(1):17-23. Review.

  10. Identification of small molecule inhibitors 2 classes • 1. Enzyme Inhibitors • Many effective strategies for identifying enzyme inhibitors. • 2. Protein-Protein Interaction Inhibitors • Difficult to identify potent inhibitors of protein-protein interactions.

  11. Methods for discovering enzyme inhibitors • High throughput screening (parallel synthesis and combinatorial chemistry) • Mechanism-based (incorporate a functionality that is unique for an enzyme enzyme class (For example, proteases) • Privileged scaffolds (kinases, phosphodiesterases) • Transition state analogs

  12. Turk B.Targeting proteases: successes, failures and future prospects. Nat Rev Drug Discov. 2006 Sep;5(9):785-99.

  13. Aspartyl Protease Inhibitors

  14. HIV Protease Inhibitors INHIBITORS OF HIV-1 PROTEASE: A “Major Success of Structure-Assisted Drug Design” Alexander Wlodawer, Jiri Vondrasek. Annual Review of Biophysics and Biomolecular Structure. Volume 27, Page 249-284, 1998

  15. HIV Protease Inhibitors

  16. HIV Protease Inhibitors Resistance

  17. More protease inhibitors • Ketones (serine and cysteine proteases) • Phosphonic and hydroxamic acids (metalloproteases) hydroxamic acids chelate the active site zinc transition state analog

  18. Protein Kinases

  19. The human genome encodes 538 Protein kinases (483 are catalytically active)

  20. Kinase Inhibitors Almost all inhibitors that have been developed bind in the ATP pocket

  21. Synthesis of kinase inhibitors Library Synthesis 10,000 Library Screening 10,000 Olomucine Cdc2/CyB: 1µM Cdk2/CyA: 1µM Hit Cdc2/CyB: 340 pM Cdk2/CyA: 340 pM Gray et. al. Science (1998) 281, 533-538.

  22. Approved kinase inhibitors 28 small molecule kinase inhibitors are now in the clinic Gleevec (Imatinib) was the first clinically approved kinase inhibitor (2003)

  23. Protein-Protein Interaction (PPI) Inhibitors • Identification of potent PPI inhibitors is very challenging. In general, standard screening strategies don’t work. • Conversion of Peptides/Proteins to Small Molecules • Innovative new strategies are needed • for example, SAR by NMR

  24. Conversion of Peptides/Proteins to Small Molecules “SAR” by NMR Abbott Laboratories (Stephen Fesik) Fragment based approach - library of small compounds (several thousands) - build up larger ligands - n fragments may yield n2 compounds NMR: 15N-HSQC of target protein (2D NMR) Requirements 3D structure of target protein (NMR or other) large quantities of 15N-labeled protein (> 100 mg) NMR assignments of backbone N and HN atoms size of protein <40 kDa solubility: protein and ligands Principle start with known protein structure and 15N assignments 15N-HSQC of protein 15N-HSQC of protein plus ligand: identify shifted peaks map these on protein surface: binding site Shuker, S. B.; Hajduk, P. J.; Meadows, R. P.;Fesik, S. W. Science 1996, 274, 1531.

  25. “SAR” by NMR

  26. “SAR” by NMR • Screen 100-5000 low molecular • weight (150 -300 MW) ligands to identify • weak binders. HSQC perturbations • identigy the site of binding • Screen for a second site of binding in • the presence of the first ligand • Use structural information to design • a linkage between the two identified ligands • ∆G(linked ligand) = ∆G(fragment 1) + • ∆G(fragment 2) + ∆G(linker) + • ∆G(cooperativity) • ∆G(linker) usually positive (entropic cost) • ∆G(cooperativity) is a non-additive effect

  27. Application: Bcl-xL/BH3 Proteins

  28. First Site Ligands First Site Ligands

  29. Second Site Ligands

  30. Linked Inhibitor

  31. (Bcl-xL-ABT-737) Nature2005 Jun 2;Vol. 435(7042):p. 677-81. J. Med Chem. 2006 Jan 26;Vol. 49(2):p. 656-63. J Med Chem. 2006 Feb 9;Vol. 49(3):p. 1165-81

More Related